Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Neuroscience
LoQus23 raises $15 million for neurodegenerative diseases
by Ryan Cross
November 26, 2021
| A version of this story appeared in
Volume 99, Issue 43
LoQus23 Therapeutics has emerged from stealth with about $15 million in seed financing from Novartis Venture Fund and Dementia Discovery Fund to develop small-molecule drugs for neurodegenerative diseases. The British start-up is focused on a class of genetic conditions called triplet repeat diseases, which include Huntington’s disease and myotonic dystrophy type 1. LoQus23 will target DNA mismatch repair proteins to slow the course of these degenerative conditions.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter